Alkermes plc Q1 2026 Earnings Recap

ALKS Q1 2026 May 8, 2026

Get alerts when ALKS reports next quarter

Alkermes shares rose 3.4% post-earnings, reflecting investor approval of robust proprietary product sales growth and early contributions from the recently acquired sleep medicine asset, LUMRYZ.

Earnings Per Share Beat

$-0.40 vs $-0.57 est.

+29.8% surprise

Revenue Beat

392911000 vs 363060500 est.

+8.2% surprise

Market Reaction

1-Day +1.37%

5-Day +7.12%

30-Day +26.58%

See ALKS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Proprietary product net sales grew 38% year-over-year to $338.1 million, driven by strong demand across psychiatry and addiction franchises.
VIVITROL sales reached $112.4 million, supported by favorable localized market dynamics; 2026 guidance reaffirmed at $460–480 million.
Psychiatry portfolio net sales included ARISTADA at $93.8 million and LYBALVI at $92.4 million, with LYBALVI TRX growing 21% year-over-year; full-year sales guidance maintained.
Favorable gross-to-net adjustments contributed approximately $14 million of upside in Q1, primarily from improved patient mix.
Integration of Avadel and the LUMRYZ launch added six weeks of commercial contribution and established Alkermes’ presence in the sleep medicine market ahead of future pipeline opportunities.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALKS on AllInvestView.

Previous Q3 2025